Trial Profile
BrUOG L301: Xofigo Following Frontline-Line Chemotherapy For Patients With Non-Small Cell Lung Cancer and Bone Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Jan 2019 Status changed from active not recruiting to completed.
- 06 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Aug 2018.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology